首页 > 最新文献

Acta Facultatis Pharmaceuticae Universitatis Comenianae最新文献

英文 中文
Study of physico-chemical properties of potential beta-adrenolytics 潜在β -肾上腺素解药的理化性质研究
Pub Date : 2014-12-30 DOI: 10.2478/afpuc-2014-0014
M. Stankovicová, Ž. Bezáková, P. Mokrý, P. Salát, M. Kocik, J. Csöllei
Abstract The aim of this paper is the study of physico-chemical properties of the chosen compounds, derivatives of 2-hydroxy-3-[2-(4-methoxyphenyl) ethylamino]propyl-4-[(alkoxycarbonyl)amino]benzoates and 2-hydroxy-3-[2-(2-methoxyphenyl)ethylamino]propyl-4-[(alkoxycarbonyl) amino]benzoates with potential ultra-short beta-adrenolytic activity. The studied compounds are different in the position of the substituent on the benzene ring in the side chain as well as in the aromatic ring in position 4 with alkyl- (methylto butyl-) carbamate. The physico-chemical characteristics, for example, lipophilicity, surface activity, adsorbability, acidobasic properties etc., are very important for the explanation of the relationship between structure and biological activity of the drug. These parameters serve as the base of quantitative structure-activity study. The goal of this work is to establish the spectral characteristics of studied compounds in UV-area, pKa values, the parameters of lipophilicity (the values of Rf and RM from thin layer chromatography, retention time t´R and capacity factor k´ from liquid chromatography and experimental partition coefficients log P´ values), surface tension, critical micelle concentrations, the adsorbability of compounds expressed by percent of adsorbed compound on active charcoal β% as well as by Freundlich adsorption isotherms. The obtained values are correlated with the parameters characterising the size of molecule, for example, the number of carbon atoms on carbamate functional group.
摘要本文的目的是研究所选化合物的物理化学性质,2-羟基-3-[2-(4-甲氧基苯基)乙胺]丙基-4-[(烷氧基)氨基]苯甲酸盐和2-羟基-3-[2-(2-甲氧基苯基)乙胺]丙基-4-[(烷氧基)氨基]苯甲酸盐具有潜在的超短-肾上腺素溶解活性。所研究的化合物在侧链苯环上的取代基位置不同,在与氨基甲酸烷基(甲基-丁基-)氨基甲酸酯的芳香环上的取代基位置也不同。药物的理化性质,如亲脂性、表面活性、吸附性、酸碱性等,对于解释药物的结构与生物活性之间的关系是非常重要的。这些参数是定量构效研究的基础。本工作的目的是建立所研究化合物在紫外区的光谱特征,pKa值,亲脂性参数(薄层色谱的Rf和RM值,液相色谱的保留时间t´R和容量因子k´和实验分配系数log P´值),表面张力,临界胶束浓度,用吸附化合物在活性炭上的百分比β%和Freundlich吸附等温线表示化合物的吸附性。所得值与表征分子大小的参数相关,例如氨基甲酸酯官能团上的碳原子数。
{"title":"Study of physico-chemical properties of potential beta-adrenolytics","authors":"M. Stankovicová, Ž. Bezáková, P. Mokrý, P. Salát, M. Kocik, J. Csöllei","doi":"10.2478/afpuc-2014-0014","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0014","url":null,"abstract":"Abstract The aim of this paper is the study of physico-chemical properties of the chosen compounds, derivatives of 2-hydroxy-3-[2-(4-methoxyphenyl) ethylamino]propyl-4-[(alkoxycarbonyl)amino]benzoates and 2-hydroxy-3-[2-(2-methoxyphenyl)ethylamino]propyl-4-[(alkoxycarbonyl) amino]benzoates with potential ultra-short beta-adrenolytic activity. The studied compounds are different in the position of the substituent on the benzene ring in the side chain as well as in the aromatic ring in position 4 with alkyl- (methylto butyl-) carbamate. The physico-chemical characteristics, for example, lipophilicity, surface activity, adsorbability, acidobasic properties etc., are very important for the explanation of the relationship between structure and biological activity of the drug. These parameters serve as the base of quantitative structure-activity study. The goal of this work is to establish the spectral characteristics of studied compounds in UV-area, pKa values, the parameters of lipophilicity (the values of Rf and RM from thin layer chromatography, retention time t´R and capacity factor k´ from liquid chromatography and experimental partition coefficients log P´ values), surface tension, critical micelle concentrations, the adsorbability of compounds expressed by percent of adsorbed compound on active charcoal β% as well as by Freundlich adsorption isotherms. The obtained values are correlated with the parameters characterising the size of molecule, for example, the number of carbon atoms on carbamate functional group.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"43 1","pages":"49 - 54"},"PeriodicalIF":0.0,"publicationDate":"2014-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76802351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The variability of secondary metabolites in mentha × piperita cv . ‘perpeta’ during the development of inflorescence 薄荷次生代谢物的变异。在花序发育期间为“永续型”
Pub Date : 2014-12-30 DOI: 10.2478/afpuc-2014-0012
S. Fialová, D. Tekeľová, E. Svajdlenka, P. Potúček, K. Jakubová, D. Grančai
Abstract Mentha × piperita (L.) Huds. of the family Lamiaceae is a very important species for commercial exploitation due to the high content of essential oil. Besides the essential oils, there are also other significant secondary metabolites in peppermint, especially flavonoids and hydroxycinnamic derivatives. In this study, we evaluate the variability of essential oil constituents and of phenolic compounds in the leaves of M. × piperita during the development of inflorescence. Similar studies, dealing with the variation of the essential oils and its composition, have been performed in the past, but no attention was paid to the variation of other secondary metabolites. We examined M. × piperita cv. ‘Perpeta’, the domestic cultivar. The plants were cultivated in the climatic conditions of south-west Slovakia. The contents of secondary metabolites were investigated in the week periods, from the beginning of inflorescence formation to the end of flowering. The yield and the quality of essential oil have been carried out by distillation and gas chromatography mass spectrometry (GC-MS). The phenolic substances were analysed using spectrophotometric methods according to European Pharmacopoeia. The highest contents of phenolic substances have been found in leaves of plants during the flowering phenophase, the same stage when essential oil of mint also achieves the highest quality.
薄荷(Mentha × piperita)Huds。由于其精油含量高,是一种具有重要商业开发价值的植物。除精油外,薄荷中还有其他重要的次生代谢产物,尤其是黄酮类化合物和羟基肉桂衍生物。在本研究中,我们评估了花椒叶片中精油成分和酚类化合物在花序发育过程中的变异性。过去已经进行了类似的研究,处理精油及其成分的变化,但没有注意到其他次生代谢物的变化。我们检测了m.x piperita cv。'佩尔塔',国内栽培品种。这些植物是在斯洛伐克西南部的气候条件下种植的。从花序形成开始到开花结束的一周时间内,研究了次生代谢物的含量。采用蒸馏、气相色谱-质谱(GC-MS)对精油的收率和质量进行了测定。根据欧洲药典规定,采用分光光度法对酚类物质进行分析。植物叶片中酚类物质含量最高的时期是开花物候期,同一时期薄荷精油的质量也达到最高。
{"title":"The variability of secondary metabolites in mentha × piperita cv . ‘perpeta’ during the development of inflorescence","authors":"S. Fialová, D. Tekeľová, E. Svajdlenka, P. Potúček, K. Jakubová, D. Grančai","doi":"10.2478/afpuc-2014-0012","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0012","url":null,"abstract":"Abstract Mentha × piperita (L.) Huds. of the family Lamiaceae is a very important species for commercial exploitation due to the high content of essential oil. Besides the essential oils, there are also other significant secondary metabolites in peppermint, especially flavonoids and hydroxycinnamic derivatives. In this study, we evaluate the variability of essential oil constituents and of phenolic compounds in the leaves of M. × piperita during the development of inflorescence. Similar studies, dealing with the variation of the essential oils and its composition, have been performed in the past, but no attention was paid to the variation of other secondary metabolites. We examined M. × piperita cv. ‘Perpeta’, the domestic cultivar. The plants were cultivated in the climatic conditions of south-west Slovakia. The contents of secondary metabolites were investigated in the week periods, from the beginning of inflorescence formation to the end of flowering. The yield and the quality of essential oil have been carried out by distillation and gas chromatography mass spectrometry (GC-MS). The phenolic substances were analysed using spectrophotometric methods according to European Pharmacopoeia. The highest contents of phenolic substances have been found in leaves of plants during the flowering phenophase, the same stage when essential oil of mint also achieves the highest quality.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"348 1","pages":"21 - 25"},"PeriodicalIF":0.0,"publicationDate":"2014-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74828324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
„Z”-scores of anthropometric and motor parameters of girls in aerobic gymnastics “Z”-女子有氧体操人体测量和运动参数得分
Pub Date : 2014-12-30 DOI: 10.2478/afpuc-2014-0008
M. Tibenska, H. Medeková
Abstract This study presents the evaluation of chosen anthropometric and motor parameters in group of female junior competitors throughout the course of 2-year preparation of aerobic gymnastics by means of Z-scores. The observed group consisted of 12 girls (average age at the beginning of observance 14.08 ± 1.19 years). Evaluation of anthropometric (body height, body weight, body mass index, percentage of body fat, acting body weight) and motor parameters (sit-ups in 30 seconds and 60 seconds, pull-ups to bar, modified push-ups, standing long jump, backwards tandem walking, shuttle run 4×10 m, Jacík’s test) was carried out in standard conditions in nine girls at 3-month intervals. It has been confirmed that female probands with higher Z-score of motor parameters together with lower Z-score of anthropometric parameters achieved higher sport performance during the 2-year observance at competitions, with an exception of one such proband.
摘要本研究采用z分数法对一组初级女子健美操运动员在2年的有氧体操训练过程中所选择的人体测量和运动参数进行评价。观察组12例,平均年龄(14.08±1.19)岁。在标准条件下,每隔3个月对9名女孩进行人体测量(身高、体重、体重指数、体脂百分比、表演体重)和运动参数(30秒和60秒仰卧起坐、引体向上、改良俯卧撑、立定跳远、向后双人步行、穿梭跑4×10 m、Jacík’s测试)的评估。研究证实,运动参数z得分较高、人体测量参数z得分较低的女性先证者在2年的比赛中取得了较高的运动成绩,但有一个先证者例外。
{"title":"„Z”-scores of anthropometric and motor parameters of girls in aerobic gymnastics","authors":"M. Tibenska, H. Medeková","doi":"10.2478/afpuc-2014-0008","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0008","url":null,"abstract":"Abstract This study presents the evaluation of chosen anthropometric and motor parameters in group of female junior competitors throughout the course of 2-year preparation of aerobic gymnastics by means of Z-scores. The observed group consisted of 12 girls (average age at the beginning of observance 14.08 ± 1.19 years). Evaluation of anthropometric (body height, body weight, body mass index, percentage of body fat, acting body weight) and motor parameters (sit-ups in 30 seconds and 60 seconds, pull-ups to bar, modified push-ups, standing long jump, backwards tandem walking, shuttle run 4×10 m, Jacík’s test) was carried out in standard conditions in nine girls at 3-month intervals. It has been confirmed that female probands with higher Z-score of motor parameters together with lower Z-score of anthropometric parameters achieved higher sport performance during the 2-year observance at competitions, with an exception of one such proband.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"26 1","pages":"55 - 58"},"PeriodicalIF":0.0,"publicationDate":"2014-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90363033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Spending of medical devices in Slovakia 斯洛伐克医疗器械支出
Pub Date : 2014-12-30 DOI: 10.2478/afpuc-2014-0009
I. Malovecká, J. Vidrová, D. Mináriková, V. Foltán
Abstract Medical devices (MD), together with pharmacotherapy are supportive treatment of many acute and chronic diseases. MD as a part of medical technologies lead to more effective treatment, faster patient recovery and a reduced risk of complications. Many MD are reimbursed from public health insurance funds entirely; for others, particularly advanced functional types of MD, there must be patient participation on price or they can buy them according own decision (direct sale). The target of this study is to analyze the data from paid databases of National Center for Health Information (NCHI) that collects the outputs of provided healthcare. The most recent data were from 1.1.2013 to 30.9.2013. According to NCHI, apart from community pharmacies, there are 226 registered establishments that sold MD until 30.9.2013. Their specialization included dispensing MD (n=163), dispensing orthopaedic devices (n=48) and dispensing audioprosthetic devices (n=15). In the observed period, average monthly spending on MD were 10.1 million packages and 14 million €. Average monthly spending on reimbursed MD were 8.8 million packages and 12.9 million €. The groups with the largest shares were MD for incontinence and urinary retention, 7.7 million packages (86.9%) and 3.9 million € (30.7%); plasters and bandaging materials, 0.5 million packages (6.0%) and 1.3 million € (10.1%); MD for ostomies, 0.4 million packages (4.5%) and 1 million € (8.0%); and the MD for diabetics group, 0.1 million packages (1.4%) and 1.6 million € (12.8%). Direct sales of MD per month on average reached 1.3 million packages and 1.1 million €. The groups with largest shares were MD for incontinence and urinary retention, 629,660 packages (50.3%) and 291,919 € (26.2%); plasters and bandaging materials, 388,111 packages (31.0%) and 227,119 € (20.4%); and MD for diabetics, 56,014 packages (4.5%) and 81,721 € (7.3%).
医疗器械与药物治疗是许多急慢性疾病的辅助治疗手段。医学作为医疗技术的一部分,可以带来更有效的治疗、更快的患者康复和更低的并发症风险。许多医学博士完全由公共健康保险基金报销;对于其他的,特别是高级功能类型的MD,必须有患者参与价格,或者他们可以根据自己的决定购买(直销)。本研究的目的是分析来自国家卫生信息中心(NCHI)收费数据库的数据,该数据库收集了所提供医疗保健的输出。最新数据为2013年1月1日至2013年9月30日。根据NCHI的数据,截至2013年9月30日,除社区药房外,共有226家注册机构销售MD。他们的专业包括分配MD (n=163),分配骨科设备(n=48)和分配听觉假肢设备(n=15)。在观察期间,MD的平均每月支出为1010万包和1400万欧元。报销MD的平均每月支出为880万包裹和1290万欧元。占比最大的是用于尿失禁和尿潴留的MD, 770万包(86.9%)和390万欧元(30.7%);膏药和包扎材料,50万包(6.0%)和130万欧元(10.1%);MD用于造口,40万包(4.5%)和100万欧元(8.0%);糖尿病组的MD为10万包(1.4%)和160万欧元(12.8%)。每月MD的直接销售额平均达到130万包和110万欧元。占比最大的是MD治疗尿失禁和尿潴留,629660包(50.3%)和291919欧元(26.2%);膏药和包扎材料,388,111包(31.0%)和227,119欧元(20.4%);糖尿病患者的MD为56,014个套餐(4.5%)和81,721欧元(7.3%)。
{"title":"Spending of medical devices in Slovakia","authors":"I. Malovecká, J. Vidrová, D. Mináriková, V. Foltán","doi":"10.2478/afpuc-2014-0009","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0009","url":null,"abstract":"Abstract Medical devices (MD), together with pharmacotherapy are supportive treatment of many acute and chronic diseases. MD as a part of medical technologies lead to more effective treatment, faster patient recovery and a reduced risk of complications. Many MD are reimbursed from public health insurance funds entirely; for others, particularly advanced functional types of MD, there must be patient participation on price or they can buy them according own decision (direct sale). The target of this study is to analyze the data from paid databases of National Center for Health Information (NCHI) that collects the outputs of provided healthcare. The most recent data were from 1.1.2013 to 30.9.2013. According to NCHI, apart from community pharmacies, there are 226 registered establishments that sold MD until 30.9.2013. Their specialization included dispensing MD (n=163), dispensing orthopaedic devices (n=48) and dispensing audioprosthetic devices (n=15). In the observed period, average monthly spending on MD were 10.1 million packages and 14 million €. Average monthly spending on reimbursed MD were 8.8 million packages and 12.9 million €. The groups with the largest shares were MD for incontinence and urinary retention, 7.7 million packages (86.9%) and 3.9 million € (30.7%); plasters and bandaging materials, 0.5 million packages (6.0%) and 1.3 million € (10.1%); MD for ostomies, 0.4 million packages (4.5%) and 1 million € (8.0%); and the MD for diabetics group, 0.1 million packages (1.4%) and 1.6 million € (12.8%). Direct sales of MD per month on average reached 1.3 million packages and 1.1 million €. The groups with largest shares were MD for incontinence and urinary retention, 629,660 packages (50.3%) and 291,919 € (26.2%); plasters and bandaging materials, 388,111 packages (31.0%) and 227,119 € (20.4%); and MD for diabetics, 56,014 packages (4.5%) and 81,721 € (7.3%).","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"58 1","pages":"35 - 41"},"PeriodicalIF":0.0,"publicationDate":"2014-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77506545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Neutrons in studies of phospholipid bilayers and bilayer–drug interaction. I. Basic principles and neutron diffraction 磷脂双分子层及双分子层与药物相互作用研究中的中子。1、基本原理及中子衍射
Pub Date : 2014-12-30 DOI: 10.2478/afpuc-2014-0010
M. Belička, Ferdinand Devínsky, P. Balgavý
Abstract In our paper, we demonstrate several possibilities of using neutrons in pharmaceutical research with the help of examples of scientific results achieved at our University. In this first part, basic properties of neutrons and elementary principles of elastic scattering of thermal neutrons are described. Results of contrast variation neutron diffraction on oriented phospholipid bilayers with intercalated local anaesthetic or cholesterol demonstrate the potential of this method at determination of their position in bilayers. Diffraction experiments with alkan-1-ols located in the bilayers revealed their influence on bilayer thickness as a function of their alkyl chain length.
在本文中,我们以我校的科研成果为例,论证了在药物研究中使用中子的几种可能性。第一部分介绍了中子的基本性质和热中子弹性散射的基本原理。用局部麻醉剂或胆固醇对定向磷脂双分子层的对比变化中子衍射结果证明了这种方法在确定它们在双分子层中的位置方面的潜力。对双层中烷烃-1-醇的衍射实验表明,它们对双层厚度的影响是其烷基链长度的函数。
{"title":"Neutrons in studies of phospholipid bilayers and bilayer–drug interaction. I. Basic principles and neutron diffraction","authors":"M. Belička, Ferdinand Devínsky, P. Balgavý","doi":"10.2478/afpuc-2014-0010","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0010","url":null,"abstract":"Abstract In our paper, we demonstrate several possibilities of using neutrons in pharmaceutical research with the help of examples of scientific results achieved at our University. In this first part, basic properties of neutrons and elementary principles of elastic scattering of thermal neutrons are described. Results of contrast variation neutron diffraction on oriented phospholipid bilayers with intercalated local anaesthetic or cholesterol demonstrate the potential of this method at determination of their position in bilayers. Diffraction experiments with alkan-1-ols located in the bilayers revealed their influence on bilayer thickness as a function of their alkyl chain length.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"50 1","pages":"1 - 11"},"PeriodicalIF":0.0,"publicationDate":"2014-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88471546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Complex Multidisciplinary Follow-Up Of Children With Neurofibromatosis Type 1 1型神经纤维瘤病患儿复杂的多学科随访
Pub Date : 2014-08-30 DOI: 10.2478/afpuc-2014-0003
A. Bolčeková, A. Hlavatá, A. Zat’ková, M. Némethová, M. Holobradá, P. Sýkora, A. Gerinec, K. Husáková, D. Ilencikova, L. Kovács
Abstract Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant disorders with mainly mild cutaneous manifestations. Some patients with NF1, however, develop severe complications such as progressive optic pathway glioma, plexiform neurofibroma or malignant peripheral nerve sheath tumour. Due to potentially progressive and asymptomatic course of the disease, patients with NF1 require a regular multidisciplinary follow-up in coordination with various specialties and early intervention. In this article, we summarise our long-term experience with multidisciplinary follow-up of NF1 patients in the Centre for Neurofibromatosis Type 1 patients at the Children's University Hospital in Bratislava.
1型神经纤维瘤病(NF1)是最常见的常染色体显性遗传病之一,以轻度皮肤表现为主。然而,一些NF1患者会出现严重的并发症,如进行性视神经通路胶质瘤、丛状神经纤维瘤或恶性周围神经鞘肿瘤。由于NF1的病程可能进展且无症状,因此NF1患者需要定期进行多学科随访,协调各专科和早期干预。在这篇文章中,我们总结了我们在布拉迪斯拉发儿童大学医院1型神经纤维瘤病中心对NF1患者进行多学科随访的长期经验。
{"title":"Complex Multidisciplinary Follow-Up Of Children With Neurofibromatosis Type 1","authors":"A. Bolčeková, A. Hlavatá, A. Zat’ková, M. Némethová, M. Holobradá, P. Sýkora, A. Gerinec, K. Husáková, D. Ilencikova, L. Kovács","doi":"10.2478/afpuc-2014-0003","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0003","url":null,"abstract":"Abstract Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant disorders with mainly mild cutaneous manifestations. Some patients with NF1, however, develop severe complications such as progressive optic pathway glioma, plexiform neurofibroma or malignant peripheral nerve sheath tumour. Due to potentially progressive and asymptomatic course of the disease, patients with NF1 require a regular multidisciplinary follow-up in coordination with various specialties and early intervention. In this article, we summarise our long-term experience with multidisciplinary follow-up of NF1 patients in the Centre for Neurofibromatosis Type 1 patients at the Children's University Hospital in Bratislava.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77059468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Creation Of The National Registry Of Rare Diseases In The Slovak Republic 在斯洛伐克共和国建立国家罕见疾病登记处
Pub Date : 2014-08-30 DOI: 10.2478/afpuc-2014-0005
F. Cisárik, A. Baráková
Abstract The creation of a registry of patients with rare diseases is a priority of the National Strategy for Rare Diseases as well as of the National Plan for Rare Diseases. Knowledge of the real number of patients with rare diseases would thus, in addition to basic clinical information, represent an important point in planning health and social care. The presented work introduces points of departure which constitute the basis of a new specific National Registry of Patients with Rare Diseases in the Slovak Republic. Its creation builds on the existing registries as well as on the structure of health care in the Slovak Republic. With the protection of personal data in mind, the collection of data will be carried out by the National Centre of Health Information (NCHI), which will also use the existing tool in the process of creation. Thanks to the cooperation between NCHI and the Slovak Society of Medical Genetics, NCHI developed separate reporting forms on rare diseases according to OMIM (Online Mendelian Inheritance in Man) and ORPHANET rare disease coding (ORPHA codes of rare diseases), and the International classification of diseases code (ICD 10). The activities also include cooperation with the existing registries (part of which are rare diseases). For example National Registry of Congenital Developmental Heart Defects, national register of neuromuscular disorders, oncologic register or register of diabetes mellitus. Gathering the information from these registries we will extend the data about rare diseases in the Slovak republic. At the international level the participation in the European Surveillance of Congenital Anomalies (EUROCAT) is important.
建立罕见病患者登记册是国家罕见病战略和国家罕见病计划的优先事项。因此,除了基本的临床资料外,了解罕见疾病患者的实际人数是规划保健和社会保健的一个重要方面。所介绍的工作介绍了出发点,这些出发点构成了斯洛伐克共和国新的特殊的国家罕见疾病患者登记册的基础。它的建立是基于斯洛伐克共和国现有的登记制度和保健结构。为保护个人数据,数据收集工作将由国家卫生信息中心(NCHI)负责,该中心在创建过程中也将使用现有工具。由于国家遗传信息中心与斯洛伐克医学遗传学会之间的合作,国家遗传信息中心根据OMIM(人类在线孟德尔遗传)和ORPHANET罕见疾病编码(罕见疾病的ORPHA代码)以及国际疾病分类代码(ICD 10)制定了单独的罕见疾病报告表格。这些活动还包括与现有的登记处(其中一部分是罕见疾病登记处)进行合作。例如,全国先天性发育性心脏缺陷登记,全国神经肌肉疾病登记,肿瘤登记或糖尿病登记。从这些登记处收集信息后,我们将扩大关于斯洛伐克共和国罕见疾病的数据。在国际一级,参与欧洲先天性异常监测(EUROCAT)是重要的。
{"title":"The Creation Of The National Registry Of Rare Diseases In The Slovak Republic","authors":"F. Cisárik, A. Baráková","doi":"10.2478/afpuc-2014-0005","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0005","url":null,"abstract":"Abstract The creation of a registry of patients with rare diseases is a priority of the National Strategy for Rare Diseases as well as of the National Plan for Rare Diseases. Knowledge of the real number of patients with rare diseases would thus, in addition to basic clinical information, represent an important point in planning health and social care. The presented work introduces points of departure which constitute the basis of a new specific National Registry of Patients with Rare Diseases in the Slovak Republic. Its creation builds on the existing registries as well as on the structure of health care in the Slovak Republic. With the protection of personal data in mind, the collection of data will be carried out by the National Centre of Health Information (NCHI), which will also use the existing tool in the process of creation. Thanks to the cooperation between NCHI and the Slovak Society of Medical Genetics, NCHI developed separate reporting forms on rare diseases according to OMIM (Online Mendelian Inheritance in Man) and ORPHANET rare disease coding (ORPHA codes of rare diseases), and the International classification of diseases code (ICD 10). The activities also include cooperation with the existing registries (part of which are rare diseases). For example National Registry of Congenital Developmental Heart Defects, national register of neuromuscular disorders, oncologic register or register of diabetes mellitus. Gathering the information from these registries we will extend the data about rare diseases in the Slovak republic. At the international level the participation in the European Surveillance of Congenital Anomalies (EUROCAT) is important.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85002837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Alkaptonuria and Ochronosis – Experience From Slovakia 尿酸和老年痴呆——斯洛伐克的经验
Pub Date : 2014-08-30 DOI: 10.2478/afpuc-2014-0001
J. Rovenský, T. Urbánek, R. Imrich
Abstract Alkaptonuria is a rare inherited genetic disorder of phenylalanine and tyrosine metabolism. This is an autosomal recessive condition that is caused due to a defect in the enzyme homogentisate 1,2-dioxygenase, which participates in the degradation of tyrosine. As a result, homogentisic acid and its oxide accumulate in the blood and are excreted in urine in large amounts. The polymer of homogentisic acid called alkapton impregnates bradotrophic tissues.
摘要尿酸尿症是一种罕见的遗传性苯丙氨酸和酪氨酸代谢疾病。这是一种常染色体隐性遗传病,是由于参与酪氨酸降解的酶均质1,2-双加氧酶的缺陷引起的。结果,均质酸及其氧化物在血液中积累,并随尿液大量排出。均质酸的聚合物称为alkapton,它浸渍在营养组织中。
{"title":"Alkaptonuria and Ochronosis – Experience From Slovakia","authors":"J. Rovenský, T. Urbánek, R. Imrich","doi":"10.2478/afpuc-2014-0001","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0001","url":null,"abstract":"Abstract Alkaptonuria is a rare inherited genetic disorder of phenylalanine and tyrosine metabolism. This is an autosomal recessive condition that is caused due to a defect in the enzyme homogentisate 1,2-dioxygenase, which participates in the degradation of tyrosine. As a result, homogentisic acid and its oxide accumulate in the blood and are excreted in urine in large amounts. The polymer of homogentisic acid called alkapton impregnates bradotrophic tissues.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85504211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and Treatment of Hairy Cell Leukaemia 毛细胞白血病的特点及治疗
Pub Date : 2014-08-30 DOI: 10.2478/afpuc-2014-0002
R. Greksák
Abstract Hairy cell leukaemia (HCL) is a rare chronic indolent lymphoproliferative disease of B-lymphocytes. It always infiltrates the spleen, bone marrow or other organs and is also present in the peripheral blood in more than 95% of cases. The disease takes its name from its characteristic wrinkled surface with hair-like projections. The prognosis of this infaust diagnosis has dramatically changed since the 1980s through more precise diagnosis and efective treatment with purine analogues (1984, 2-deoxycoformy-cine (2-dCF); 1990, 2-chlorodeoxyadenosine (2-CdA)). In our group of 38 patients, we confrmed the diagnostic possibilities and their accuracy; in addition to morphological examination, these include fow cytometric detection of typical surface CD antigens and immunohistochemical recognition of hairy cells in the trephine biopsy. The treatment percentage in the number of response rates (RRs) (100%), complete remissions (CRs) (79%) and overall survival of patients is comparable with previously known data. Overall survival rate without symptoms of disease for more than 10 years after treatment is 87% (33/38). The presence and quantity of minimal residual disease (MRD) after frst-line treatment in bone marrow determine subsequent progression or relapse of the disease, sometimes even occurring many years after the treatment. Probably some new pharmacotherapeutical possibilities (monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors or inhibitors of B-Raf enzyme) could demonstrate the ability to eliminate MRD and cure it in relapsed patients or patients refractory to purine analogues. HCL has become an oncological disease with a relatively good prognosis and long-term survival after standard treatment with purine analogues despite the persistence of indolent MRD in the bone marrow at varying degree of residual infiltration intensity.
毛细胞白血病(HCL)是一种罕见的慢性惰性b淋巴细胞增生性疾病。它总是浸润脾、骨髓或其他器官,95%以上的病例也存在于外周血中。这种疾病之所以得名,是因为它的表面有皱纹,有毛发状的突起。自20世纪80年代以来,通过更精确的诊断和嘌呤类似物的有效治疗,这种错误诊断的预后发生了巨大变化(1984年,2-脱氧辅酶甲素(2-dCF);1990, 2-氯脱氧腺苷(2-CdA)。在本组38例患者中,我们证实了诊断的可能性及其准确性;除了形态学检查,这些包括流式细胞术检测典型的表面CD抗原和免疫组织化学识别毛细胞在环钻活检。治疗在缓解率(rr)(100%)、完全缓解(cr)(79%)和患者总生存率中的百分比与先前已知的数据相当。治疗后10年以上无疾病症状的总生存率为87%(33/38)。一线治疗后骨髓中微小残留病(MRD)的存在和数量决定了疾病的后续进展或复发,有时甚至发生在治疗多年后。也许一些新的药物治疗可能性(单克隆抗体、免疫毒素、酪氨酸激酶抑制剂或B-Raf酶抑制剂)可以证明有能力消除MRD并治愈复发患者或对嘌呤类似物难治的患者。尽管骨髓中仍存在不同程度残余浸润强度的无痛性MRD,但经嘌呤类似物标准治疗后,HCL已成为一种预后较好、生存期较长的肿瘤疾病。
{"title":"Characteristics and Treatment of Hairy Cell Leukaemia","authors":"R. Greksák","doi":"10.2478/afpuc-2014-0002","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0002","url":null,"abstract":"Abstract Hairy cell leukaemia (HCL) is a rare chronic indolent lymphoproliferative disease of B-lymphocytes. It always infiltrates the spleen, bone marrow or other organs and is also present in the peripheral blood in more than 95% of cases. The disease takes its name from its characteristic wrinkled surface with hair-like projections. The prognosis of this infaust diagnosis has dramatically changed since the 1980s through more precise diagnosis and efective treatment with purine analogues (1984, 2-deoxycoformy-cine (2-dCF); 1990, 2-chlorodeoxyadenosine (2-CdA)). In our group of 38 patients, we confrmed the diagnostic possibilities and their accuracy; in addition to morphological examination, these include fow cytometric detection of typical surface CD antigens and immunohistochemical recognition of hairy cells in the trephine biopsy. The treatment percentage in the number of response rates (RRs) (100%), complete remissions (CRs) (79%) and overall survival of patients is comparable with previously known data. Overall survival rate without symptoms of disease for more than 10 years after treatment is 87% (33/38). The presence and quantity of minimal residual disease (MRD) after frst-line treatment in bone marrow determine subsequent progression or relapse of the disease, sometimes even occurring many years after the treatment. Probably some new pharmacotherapeutical possibilities (monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors or inhibitors of B-Raf enzyme) could demonstrate the ability to eliminate MRD and cure it in relapsed patients or patients refractory to purine analogues. HCL has become an oncological disease with a relatively good prognosis and long-term survival after standard treatment with purine analogues despite the persistence of indolent MRD in the bone marrow at varying degree of residual infiltration intensity.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89908992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First Results From Expanded Newborn Screening in slovak Republic 斯洛伐克共和国扩大新生儿筛查的初步结果
Pub Date : 2014-08-30 DOI: 10.2478/afpuc-2014-0004
S. Dluholucký, M. Knapkova, M. Zahorcova
Abstract A one-and-a-half year experience with expanded newborn screening (ENBS) in Slovakia provided by means of tandem mass spectrometry (LC-MS/MS) is presented. Method ENBS was realised from dry blood samples of the regular NBS in National Screening Centre SK. The LC-MS/MS software used allowed evaluating even 73 analytes in MRM mode after cut-of limits in 99 percentile of daily values. The regular ENBS was oriented to 10 inherited metabolic disorders (IMDs), organic acids and carnitine defects (PKU/HPA, MSUD, GAI, IVA, MCAD, LCHAD, SCAD, CPT I, CPT II, CACT). Except these, many other variations of results were registered in perimeter of the method. They were individually evaluated until the confrmation or exclusion of the suspected diagnosis. Results During the one-and-a-half years, 82 892 newborns were evaluated by ENBS and 34 positive cases of IMDs were detected and confrmed, which represents a screening prevalence of 1:2438 newborns. Out of these, 24 cases were from regular ENBS (PKU/HPA, MSUD, MCAD) with an incidence of 1:3 454, and 10 additional cases at the periphery of LC-MS/MS evaluation with a prevalence of 1:8 286. Conclusion Preliminary experience and results with ENBS confrmed its high efectiveness not only in 10 IMDs included in regular ENBS, but also at perimeter of LC-MS/MS method, in which it is possible to detect additional IMDs not included in regular spectrum of ENBS. This group comprised 29% of all cases. In general, the prevalence is comparable with PKU and/or CAH.
一年半的经验,扩大新生儿筛查(ENBS)在斯洛伐克提供的手段串联质谱(LC-MS/MS)提出。方法从SK国家筛查中心的常规NBS干血样本中实现ENBS。所使用的LC-MS/MS软件允许在MRM模式下对73种分析物进行每日值99%的下限切割后的评估。常规ENBS面向10种遗传代谢紊乱(IMDs)、有机酸和肉毒碱缺陷(PKU/HPA、MSUD、GAI、IVA、MCAD、LCHAD、SCAD、CPT I、CPT II、CACT)。除此之外,在方法的周长范围内还记录了许多其他结果的变化。他们被单独评估,直到确认或排除疑似诊断。结果在1年半的时间里,共有82 892名新生儿接受ENBS检查,发现并确诊IMDs阳性病例34例,筛查率为1:2438。其中,24例来自常规ENBS (PKU/HPA, MSUD, MCAD),发病率为1:3 454,LC-MS/MS评估外周另有10例,患病率为1:8 286。结论初步经验和结果表明,该方法不仅对常规ENBS中包含的10个imd具有较高的检测效率,而且在LC-MS/MS方法的周长范围内也具有较高的检测效率,可以检测出常规ENBS谱中未包含的其他imd。这一群体占所有病例的29%。一般来说,患病率与PKU和/或CAH相当。
{"title":"First Results From Expanded Newborn Screening in slovak Republic","authors":"S. Dluholucký, M. Knapkova, M. Zahorcova","doi":"10.2478/afpuc-2014-0004","DOIUrl":"https://doi.org/10.2478/afpuc-2014-0004","url":null,"abstract":"Abstract A one-and-a-half year experience with expanded newborn screening (ENBS) in Slovakia provided by means of tandem mass spectrometry (LC-MS/MS) is presented. Method ENBS was realised from dry blood samples of the regular NBS in National Screening Centre SK. The LC-MS/MS software used allowed evaluating even 73 analytes in MRM mode after cut-of limits in 99 percentile of daily values. The regular ENBS was oriented to 10 inherited metabolic disorders (IMDs), organic acids and carnitine defects (PKU/HPA, MSUD, GAI, IVA, MCAD, LCHAD, SCAD, CPT I, CPT II, CACT). Except these, many other variations of results were registered in perimeter of the method. They were individually evaluated until the confrmation or exclusion of the suspected diagnosis. Results During the one-and-a-half years, 82 892 newborns were evaluated by ENBS and 34 positive cases of IMDs were detected and confrmed, which represents a screening prevalence of 1:2438 newborns. Out of these, 24 cases were from regular ENBS (PKU/HPA, MSUD, MCAD) with an incidence of 1:3 454, and 10 additional cases at the periphery of LC-MS/MS evaluation with a prevalence of 1:8 286. Conclusion Preliminary experience and results with ENBS confrmed its high efectiveness not only in 10 IMDs included in regular ENBS, but also at perimeter of LC-MS/MS method, in which it is possible to detect additional IMDs not included in regular spectrum of ENBS. This group comprised 29% of all cases. In general, the prevalence is comparable with PKU and/or CAH.","PeriodicalId":7321,"journal":{"name":"Acta Facultatis Pharmaceuticae Universitatis Comenianae","volume":"96 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87199216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Acta Facultatis Pharmaceuticae Universitatis Comenianae
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1